Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS08399 in MTAP-deleted Solid Tumors and Lymphoma
NCT07583771Phase 1Not yet recruiting
- Sponsor
- Akeso, Inc.
- Start
- Jun 2026
- Primary completion
- Aug 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CS08399 in pancreatic adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), solid tumor and 2 more, sponsored by Akeso, Inc. Primary endpoints: Dose-Limiting Toxicity at 34 days, Maximum Tolerated Dose and 9 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
CS08399
03
Conditions
pancreatic adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)solid tumorlymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07583771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07583771.